logo BDSP

Base documentaire

  1. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. Commentary.

    Article - En anglais


    We evaluated the efficacy of self-start therapy in women with recurrent urinary tract infections.

    Materials and Methods 

    Women with recurrent urinary tract infections received a dip slide urine culture kit and 6 tablets of norfloxacin (400 mg.). At each symptomatic urinary tract infection episode the patient performed a culture and initiated therapy.

    The culture was returned and the patient was resupplied with another kit and norfloxacin.

    Patients were seen 5 to 9 days and 4 to 6 weeks after therapy to assess treatment outcome.


    A total of 34 women were enrolled in the study and were evaluable for treatment outcomes.

    Six women followed for 74 months were asymptomatic and 9 followed for 103 months had no infections.

    A total of 28 women followed for 355 months had 84 symptomatic episodes and 25 had 67 urinary tract infections.

    Patients had symptomatic episodes at a rate of 2.8 per patient-year (range 0 to 9) and infections at a rate of 2.3 per patient-year (range 0 to 9).

    The greatest risk of symptoms of infection or infection occurred in the first 3 months and among patients with a higher rate of infection before entering the study.

    Of the 84 symptomatic episodes 78 (92%) responded clinically.

    Of 78 cultured episodes 11 (14%) were negative.

    The remaining 67 cultured documented infections were cured microbiologically 5 to 7 days after therapy.

    No adverse effects occurred. (...)

    Mots-clés Pascal : Infection, Appareil urinaire, Femme, Homme, Récidive, Initiation, Traitement, Chimiothérapie, Antibactérien, Automédication, Norfloxacine, Faisabilité, Coût, Evaluation performance, Femelle, Fluoroquinolone dérivé, Quinolone dérivé, Appareil urinaire pathologie, Voie urinaire pathologie, Economie santé

    Mots-clés Pascal anglais : Infection, Urinary system, Woman, Human, Relapse, Initiation, Treatment, Chemotherapy, Antibacterial agent, Self prescription, Norfloxacin, Feasibility, Costs, Performance evaluation, Female, Fluoroquinolone derivatives, Quinolone derivatives, Urinary system disease, Urinary tract disease, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0050181

    Code Inist : 002B02S02. Création : 31/05/1999.